Immunohistochemical staining demonstrated reduced expression of cartilage MMP13, suggesting that reducing CMPK2 and implementing anti-inflammatory treatments effectively inhibited cartilage degradation, thus mitigating the progression of RA (Figure 7H). Here, CMPK2 is linked to rheumatoid arthritis.